Most Read

The FDA and the Company have agreed to meet in-person on January 31, 2019 to discuss this matter. Remoxy is the proposed trade name for a new type

The companies have entered into a non-exclusive commercial license agreement that will allow CRISPR Therapeutics to deploy MaxCyte’s Flow Electroporation Technology to develop CRISPR/Cas9-based therapies in immuno-oncology. CRISPR

OrbiMed served as the lead new investor, along with new investors Cormorant, Ridgeback Capital Investments, Lilly Asia Ventures (LAV) and NS Investment. Harpoon’s existing investors MPM Capital, Oncology

Now available by prescription in pharmacies across the US, NOCDURNA provides adults with a fast-acting, effective treatment that targets the kidneys, the underlying cause of NP. The sublingual

It follows the successful completion of milestones set in the initial Phase 1 grant for $223,000, awarded in 2016. Both grants focus on a process known as cellular

The decision is driven by recent findings derived from a non-interventional human study utilizing a clinically validated CANscript platform. GBR 1342 is based on Glenmark’s proprietary BEAT platform

This name reflects the company’s focus on advancing the science of cytokine-based immunotherapy for the treatment of a range of cancers. Brooklyn ImmunoTherapeutics general partner and board chair

The positive topline results of the phase 3 ECHELON-2 clinical trial were announced in October 2018 and full data will be presented at the upcoming American Society of

The program’s investment has tripled the site’s GMP capacity, added new equipment for solid oral dose manufacturing and significantly increased staffing levels. Quotient Sciences CEO Mark Egerton said: